Study of immune B cells in membranous nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at immune “B cells” in people with membranous nephropathy (a kidney disease). It includes people who have received or are being considered for B-cell–depleting treatment, aiming to better understand what drives the disease and how it may respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older.
- You have membranous nephropathy confirmed by a kidney biopsy.
- The cause must be “idiopathic,” meaning doctors do not think it’s from another illness (like lupus, hepatitis B, certain cancers, or specific drugs).
- You have either already received or are being considered for a B-cell–depleting treatment as part of your usual care.
- You’re able to understand the study and sign consent (or, if you’re a healthy volunteer, you can also follow study procedures and consent).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood and tissue samples from people with membranous nephropathy, a kidney disease, to find biological markers that predict whether rituximab, a treatment, will work. The goal is to understand why some patients do not respond, which could lead to better personalized treatment.
This trial looks at how people with primary membranous nephropathy (a kidney disease that causes swelling and protein in urine) do over time with their current treatment. It helps doctors understand which treatments work best, especially for those with severe protein loss.
This study examines blood and kidney tissue samples from people with membranous nephropathy—a condition where the kidney's filtering membrane is damaged by the immune system. Researchers are trying to understand which immune markers predict how the disease will progress and respond to treatment.
This study looks at how rituximab affects immune cells in people with a type of kidney disease called membranous nephropathy. By studying blood samples, the researchers hope to understand why some people respond better to treatment, which could help guide future care.
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
This study looks for specific proteins (autoantibodies) in your blood that may be linked to certain kidney diseases. It aims to better understand the immune system's role in minimal change disease and FSGS, which could lead to better treatments.
Hear when a new Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.